不同水平血清雌二醇不改变早期子宫内膜分泌转化的时机
该随机前瞻性配对试验纳入10名健康志愿者,每人完成三个不同雌二醇(E2)浓度的子宫刺激周期,共获取30份子宫内膜活检进行全基因组转录组和甲基化分析。结果显示,生理、中度超生理和超生理E2水平下,个体内全基因组甲基化和基因表达谱均无差异,高浓度E2不改变孕酮诱导分泌转化的能力。
要点
- 超生理水平E2不改变生理水平孕酮诱导子宫内膜分泌转化的能力。
- 个体内比较显示不同E2浓度下全基因组甲基化和基因表达谱无差异。
- 刺激周期中着床率下降可能与早期孕酮升高或胚胎发育缓慢有关。
核心结论
- 高度超生理水平的E2不改变生理水平P4诱导分泌转化的能力。
- 刺激周期中着床率下降可能源于早期P4升高后的胚胎-子宫内膜不同步或缓慢孵化的胚胎,与E2升高幅度无关。
研究设计与样本
- 随机、前瞻性配对试验,纳入10名无不孕史的健康志愿者,在单个大型不孕症中心进行。
- 每名参与者随机顺序完成三个不同E2浓度的子宫刺激周期:生理(约180 pg/ml)、中度超生理(600-800 pg/ml)或超生理(2000 pg/ml)。
- 使用戊酸雌二醇维持稳定E2水平12天,随后肌注油剂孕酮10 mg/天共两剂,之后进行子宫内膜活检。
- 共30份子宫内膜活检纳入全基因组转录组和甲基化分析。
主要发现
- 生理组平均峰值E2和P4分别为275 pg/ml和4.17 ng/ml,中度组分别为910 pg/ml和2.69 ng/ml,超生理组分别为2043 pg/ml和2.64 ng/ml。
- 对834 913个CpG位点的M值进行主成分分析,个体内不同E2组间全基因组甲基化无差异。
- 配对分析显示同一个体在三个E2水平下基因表达谱无差异。
- 参与者间分析显示低、中、超生理组间未发现与子宫内膜生理相关的基因表达显著改变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏未用药对照以评估戊酸雌二醇的潜在效应。
- 结果来自有生育力个体,其子宫内膜反应可能与不孕人群不同。
- 尽管进行了全基因组子宫内膜评估和严谨的配对设计,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do supraphysiologic estradiol (E2) levels in the ranges attained during normal and high response superovulation cycles modify the onset of endometrial secretory transformation? SUMMARY ANSWER: Highly supraphysiologic levels of E2 do not alter the ability of physiologic levels of progesterone (P4) to induce secretory transformation. WHAT IS KNOWN ALREADY: Previous studies have demonstrated that premature P4 elevations during IVF cycles are associated with a decrement in clinical pregnancy rates after fresh embryo transfer due to shifts in the window of implantation (WOI). However, alterations in the onset of secretory transformation may not apply uniformly to all patients. High responders with supraphysiologic E2 levels accompanied by similar subtle increases in P4 have not been shown to have decreased sustained implantation rates. This prospective investigation in which whole-genome transcriptomic and methylomic analysis of the endometrium is performed for individual patients under a range of E2 concentrations brings clarity to a long-debated issue. STUDY DESIGN, SIZE, DURATION: A randomized, prospective and paired trial was conducted in which 10 participants were enrolled and randomized to the order in which they completed three distinct uterine stimulation cycles, each at a specific E2 concentration: physiologic (∼180 pg/ml), moderately supraphysiologic (600-800 pg/ml) or supraphysiologic (2000 pg/ml). Target E2 ranges were selected to mimic those seen in natural, controlled ovarian stimulation and IVF cycles. E2 valerate was administered in order to maintain stable E2 levels for 12 days followed by intramuscular P4 in oil 10 mg/day for two doses, after which an endometrial biopsy was performed. A total of 30 endometrial biopsies were included in a whole-genome transcriptomic and methylomic analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Healthy volunteers without a history of infertility were included in this study at a single large infertility center. DNA was isolated from the endometrial biopsy specimens and bisulfite sequencing was performed to construct a methylation array. Differential methylation analysis was conducted based on differences in M-values of individuals across treatment groups for each probe as well as carrying out t-tests. RNA was isolated for RNA-Seq analysis and gene expression values were compared using DESeq2. All analyses were performed in a pairwise fashion to compare among the three stimulation cycles within individuals and secondarily to compare all participants in each of the cycles. MAIN RESULTS AND THE ROLE OF CHANCE: The mean peak E2 and P4 levels were 275 pg/ml and 4.17 ng/ml in the physiologic group, 910 pg/ml and 2.69 ng/ml in the moderate group was, and 2043 pg/ml and 2.64 ng/ml in the supraphysiologic group, respectively. Principal component analysis of 834 913 CpG sites was performed on M-values of individuals within the low, moderate and supraphysiologic conditions in a paired approach. There were no differences in genome-wide methylation within participants across E2 groups. A paired analysis revealed that gene expression profiles did not differ within the same individual at each of the three E2 levels. No significant alterations in gene expression as related to endometrial physiology were identified between the low, moderate and supraphysiologic groups in an inter-participant analysis. LIMITATIONS, REASONS FOR CAUTION: Although each participant completed a physiologic cycle in which E2 levels were maintained in a range that would simulate a natural cycle, our findings are limited by lack of an unmedicated control to assess if there was a potential effect from E2V. Additionally, our results were obtained in fertile individuals, who may have a different endometrial response compared to an infertile population. Despite the whole genomic endometrial assessment and rigorous, paired study design, the sample size was limited. WIDER IMPLICATIONS OF THE FINDINGS: Given that the endometrial response to P4 is unaffected by E2 levels in the supraphysiologic range, diminutions in implantation seen in stimulated cycles may result from embryonic-endometrial dyssynchrony following early P4 elevations or slowly blastulating embryos, which occur independently of the magnitude of the E2 rise. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Foundation for Embryonic Competence, Basking Ridge, NJ, USA. Dr E.S. reports consultancy work for The Foundation for Embryonic Competence, Basking Ridge, NJ, USA. The other authors declare no conflict of interests related to this topic. TRIAL REGISTRATION NUMBER: NCT02458404.
引用
- Osman EK, Wang T, Zhan Y, et al. Varying levels of serum estradiol do not alter the timing of the early endometrial secretory transformation. Hum Reprod. 2020. PMID: 32613240. doi:10.1093/humrep/deaa135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。